γδ T cell-based anticancer immunotherapy: Progress and possibilities

Immunotherapy

Volumn 7, Issue 9, 2015, Pages 949-951

  Meraviglia, Serena ^a   Lo Presti, Elena ^a   Dieli, Francesco ^a   Stassi, Giorgio ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

cancer; IFN ; IL 17; immunotherapy; PD 1; tumor infiltrating lymphocytes; T cells

Indexed keywords

ANGIOPOIETIN 2; GAMMA INTERFERON; INTERLEUKIN 17; LYMPHOCYTE ANTIGEN RECEPTOR;

CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CHOROID MELANOMA; CYTOKINE PRODUCTION; CYTOTOXICITY; EDITORIAL; GAMMA DELTA T LYMPHOCYTE; HUMAN; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; IMMUNOLOGY; METABOLISM; NEOPLASMS; T LYMPHOCYTE; TRANSPLANTATION;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; INTERLEUKIN-17; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84947570707     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.68     Document Type: Editorial

References (22)

1. Kobayashi H, Tanaka Y, Yagi J et al. Safety profile and antitumor effects of adoptive immunotherapy using γδ T cells against advanced renal cell carcinoma: A pilot study. Cancer Immunol. Immunother. 56, 469-476 (2007).
2. Bennouna J, Bompas E, Neidhardt EM et al. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol. Immunother. 57, 1599-1609 (2008).
3. Abe Y, Muto M, Nieda M et al. Clinical and immunological evaluation of zoledronate activated Vγ9 γδ T-cell-based immunotherapy for patients with multiple myeloma. Exp. Hematol. 37, 956-968 (2009).
4. Sakamoto M, Nakajima J, Murakawa T et al. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδ T cells: A Phase I clinical study. J. Immunother. 34, 202-211 (2011).
5. Kobayashi H, Tanaka Y, Shimmura H, Minato N, Tanabe K. Complete remission of lung metastasis following adoptive immunotherapy using activated autologous γδ T-cells in a patient with renal cell carcinoma Anticancer Res. 30, 575-579 (2010).
6. Dieli F, Vermijlen D, Fulfaro F et al. Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 67, 7450-7457 (2007).
7. Wilhelm M, Kunzmann V, Eckstein S et al. γδ T cells for immune therapy of patients with lymphoid malignancies. Blood 102, 200-206 (2003).
8. Meraviglia S, Eberl M, Vermijlen D et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin. Exp. Immunol. 161, 290-297 (2010).
9. Cordova A, Toia F, La Mendola C et al. Characterization of human γδ T lymphocytes infiltrating primary malignant melanomas. PLoS ONE 7, e49878 (2012).
10. Raspollini MR, Castiglione F, Rossi Degl'innocenti D et al. Tumor-infiltrating gamma/delta T lymphocytes are correlated with a brief disease free interval in advanced ovarian serous carcinoma. Ann. Oncol. 16, 590-596 (2005).
11. Bialasiewicz AA, Ma JX, Richard G. αβ-and γδ TCR+ lymphocyte infiltration in necrotizing choroidal melanomas. Br. J. Ophthalmol. 83, 1069-1073 (1999).
12. Inman BA, Frigola X, Harris KJ et al. Questionable relevance of γδ T lymphocytes in renal cell carcinoma. J. Immunol. 180, 3578-3584 (2008).
13. Ma C, Zhang Q, Ye J et al. Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer. J. Immunol. 189, 5029-5036 (2012).
14. Wakita D, Sumida K, Iwakura Y et al. Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis. Eur. J. Immunol. 40, 1927-1937 (2010).
15. Carmi Y, Rinott G, Dotan S et al. Microenvironment-derived IL-1 and IL-17 interact in the control of lungmetastasis. J. Immunol. 186, 3462-3471 (2011).
16. Ma S, Cheng Q, Cai Y et al. IL-17A produced by γδ T cells promotes tumor growth in hepatocellular carcinoma. Cancer Res. 74, 1969-1982 (2014).
17. Rei M, Goncalves-Sousa N, Lanca T et al. Murine CD27(-) Vγ6 (+) γδ T cells producing IL-17A promoteovarian cancer growth via mobilization of protumor small peritoneal macrophages. Proc. Natl Acad. Sci. USA 111, e3562-e3570 (2014).
18. Wu P, Wu D, Ni C et al. γδ T17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 40, 785-800 (2014).
19. Flavell RA, Sanjabi S, Wrzesinski SH, LiconaLimón P. The polarization of immune cells in the tumor environment by TGFb. Nat. Rev. Immunol. 10, 554-567 (2010)
20. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 66, 5527-5536 (2006).
21. Chen BJ, Chapuy B, Ouyang J et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus associated malignancies. Clin. Cancer Res. 19, 3462-3473 (2013).
22. Iwasaki M, Tanaka Y, Kobayashi H et al. Expression and function of PD-1 in human gamma delta T cells that recognize phosphoantigens. Eur. J. Immunol. 41, 345-355 (2011).